Member Info for Vertizea-Sun

I think e do have proof in the RNs from &th March :

Avacta also announces patient dosing in the AVA6000 Phase 1b expansion cohorts with multiple patients treated in this portion of the trial, which include three indications: (1) salivary gland cancer, (2) triple negative breast cancer and (3) high grade soft tissue sarcoma. Each arm of the Phase 1b expansion cohort will enroll 20-30 patients by the following criteria.

"a US leadership regime that doesn't care a jot about who's toes they tread on, or the amount of notice they provide for new regs."

If you think Downing Street does care I've got a bridge for sale.

HarChris.....you make a fair point but I don't think the senior non-exec's will want to be associated with a company issuing qualified accounts. Not good for their reputation. I think cash is incoming and I agree with McMuff......the board should step aside if not.

My understanding from CC is that a partnership decision is shelved until patents are granted.

Oblique was just fine.

Keep working. Retiring at 55 is only for quiche eaters.

The quarterly update stated "expected during May" for the results. I'm assuming the board could delay it until the end of June. Who cares if they are waiting on major financial news.

I think it's legitimate to ask why the date wasn't announced at the conference?

I don't have a clue where you are coming from. Product name? Trialled where? Or is just me?

I wonder if we'll get a Notice of Results before Thursday....that'll squash the commercial questions.

This was obviously unplanned....imho. No one gives three days notice for a run-of-the-mill webinar.

Or they shouldn't.

Trump's latest is bound to have some impact.....but good or bad for Avacta?

https://x.com/WhiteHouse/status/1921695676032856313

"Multiple patients had been dosed by March. We don’t know when that started"

Yes we do......before March 7th.

RNS 7th March:

"Avacta also announces patient dosing in the AVA6000 Phase 1b expansion cohorts with multiple patients treated in this portion of the trial, which include three indications: (1) salivary gland cancer, (2) triple negative breast cancer and (3) high grade soft tissue sarcoma."

Therefore.....AT LEAST six patients. And probably from the middle of February. 3 months on Wednesday.

Price mate.......Price.

"Usual Myles flannel" from January 16th. Thanks for the reminder. There's more information in this one post than in the previous one thousand others.

"New data from Avacta's Phase 1a trial for #AVA6000, specifically focusing on 10 patients with salivary gland cancer ('SGC')

- Only 1 out of 10 patients experienced tumour progression - equating to a 90% disease control rate in this set of patients.

- 5 out of 10 patients experienced tumour shrinkage (1 partial, 4 minor).

- 6 patients remain on treatment.

These are P1a patients, and have been heavily pre-treated. This is vital to note, as pre-treated patients are usually much less responsive to further treatment.

Currently, "there is no standard of care for SGC once patients have developed distant metastasis, with a five year survival rate of approximately 43%."

It's also crucial to remember that - especially when used as a monotherapy - it is extremely rare for standard doxorubicin to yield complete responses for patients. Rather, it is used predominantly for disease control.

So, to summarize: even in extremely sick patients with advanced stage SGC, and who have very little (if any) treatment options available remaining to them, AVA6000 has prevented disease progression in 90% of cases.

In contrast, in treatment-naive patients with earlier stage SGC, there currently exists no standard-of-care.

Results should improve significantly for AVA6000, when used as a first-line therapy for those patients with earlier stage SGC.

It's now patently obvious (at least to me!) that AVA6000 is on for accelerated approval for the treatment of SGC.

And that's just the beginning for AVA6000. The Phase 1b commencing now is also running cohorts for triple negative breast cancer and soft tissue sarcoma.

If pre | CISION can transform the treatability of a certain cancer by modifying a chemotherapy that gained marketing authorization from the FDA over a half-century ago, just how much is it going to transform the wider oncology landscape when used to modify the most potent warheads on the market right now, such as exatecan (eyes on #AVA6103!!!) and MMAE?

Avacta is in possession of Paul Ehrlich's Magic Bullet."

"There are so many scenarios that might unfold it is impossible to say"

.....that covered it.

"Phase 2. Not phase P1B"

Jog my memory please.....how will Avacta fund Phase 2?

Thanks to X and RAH.

https://x.com/RAH00084/status/1920734285629112592

One graph is a mouse model in osteosarcoma from #AVCT’s AVA6000 preclinical work.

The trend begins to change around day 85 as disease progression sets in.

The other graph is human data in salivary gland cancer.

Disease control rate is 91%. Median follow-up nearly doubling the benchmark.

The x-axis on the clinical data shows just how durable these responses are.

The first patient stopped taking AVA6000 around week 25.

On 16 Feb 2025 (data cut off) he was around 65 weeks without disease progression. That’s about 450 days.

Next week will be another 3 months (since last data cut off) without disease progression for this patient.

That’s around 540 days or just shy of 18 months…

Comparing the x-axis from the preclinical vs human model hammers home just how effective preCISION’s bystander effect is in-human.

When does AVA6000 find its median PFS?

Only if they want to be fired.

Such as:

"Prior phase III clinical trials of ThermoDox® failed to demonstrate statistically significant improvement in the primary endpoint, despite the fact that it was one of the most promising ongoing clinical investigations [18]. This led to the temporary suspension of the ThermoDox® study [19]."

It appears to be too late. I guess there are dozens of research studies ready to be upended by pre|CISION®

"Buy was there not about month ago,".......I'm working on it.